1 collaboration leads to big pharma or buyout! 2 six companies busy generating Millions. 3 proven growth Y/Y. 4 Trusted Provider network with global clinics. 5 Invited to prove effecacy in USA with 21 other companies in clinical trials Sep 2020 results..PIPELINE!
SP..pennies not according to market.. see pricing below!
$LAHI ..The Shiller P/E is a more reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Sector Healthcare: 30.50 Sector Texhnology: 34.40
Why Is the Regular P/E Ratio Deceiving?
The regular P/E uses the ratio of the S&P 500 index over the trailing-12-month earnings of S&P 500 companies. During economic expansions, companies have high profit margins and earnings. The P/E ratio then becomes artificially low due to higher earnings. During recessions, profit margins are low and earnings are low. Then the regular P/E ratio becomes higher. It is most obvious in the chart below:
We’re positioning Adimarket to become the largest e-commerce marketplace for all things regenerative medicine,” says Benito Novas, founder and CEO of Global Stem Cells Group.
The Shiller P/E is a more reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
LAHO!..CEO Announces..New Stem Cell Center in Valencia, Spain
..“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.” https://www.otcmarkets.com/stock/LAHO/news/story?e&id=1376239
Global Stem Cells Group has named Aesthetic Polyclinic in Abu Dhabi, UAE, exclusive representative for GSCG in that city.
Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development. http://www.stemcellsgroup.com/management/
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
..The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
GSCG is #1 Competitor for Biostems Tech $1.52 Dark Defunct GCSG is #1 competitor for Beike Biotechnology. GSCG is #1 competitor of Global Institute Of Stem Cell Therapy And Research!
..$LAHO GSCG clinical trial expected completion 2020! Studies a U.S. FDA-regulated Device Product: YES “Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth,” says the US National Institutes of Health. “In many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive
Market cap: $2.09 billion; current share price: $24.25 Market cap: $226.15 Million; current share price: $1.83 Market cap: $161.84 million; current share price: $1.47 Market cap: $267.60 million; current share price: $19.10 Market cap: $392.71 million; current share price: $11.25 Market cap: $64.63 million; current share price: $3.43 Market cap: $54.74 million; current share price: $5.78 Market cap: $11.05 million; current share price: $0.31 Market cap: $29.88 million; current share price: $2.75 Market cap: $28.40 million; current share price: $1.30 https://investingnews.com/daily/life-science-investing/genetics-investing/top-stem-cell-nasdaq/ https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149422974
..Bioheart, Inc. (otcqb:BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
Global Stem Cells Group to Host Stem Cells and Regenerative ... ISSCA Physicians looking for new alternatives to improve the quality of life of their patients through emerging regenerative medicine protocols..
We’re positioning Adimarket to become the largest e-commerce marketplace for all things regenerative medicine,” says Benito Novas, founder and CEO of Global Stem Cells Group.
The Shiller P/E is a more reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Estimated Study Start Date : May 13, 2019 Estimated Primary Completion Date : September 15, 2020 Estimated Study Completion Date : November 1, 2020 https://clinicaltrials.gov/ct2/show/NCT03752827
LAHO!..CEO Announces..New Stem Cell Center in Valencia, Spain
..“We are pleased to be able to open the doors on a new Stem Cells Center in Europe,” noted Novas. “The GSCG is continually exploring opportunities to deliver new stem-cell based treatment options to patients across Europe, and the Valencia center gives us the opportunity to do this while meeting our strategic mission to expand our presence in Europe.” https://www.otcmarkets.com/stock/LAHO/news/story?e&id=1376239 [color=red]
Global Stem Cells Group has named Aesthetic Polyclinic in Abu Dhabi, UAE, exclusive representative for GSCG in that city.
Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development. http://www.stemcellsgroup.com/management/
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
..The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
GSCG is #1 Competitor for Biostems Tech $1.52 Dark Defunct GCSG is #1 competitor for Beike Biotechnology. GSCG is #1 competitor of Global Institute Of Stem Cell Therapy And Research!
“Stem cells have the remarkable potential to develop into many different cell types in the body during early life and growth,” says the US National Institutes of Health. “In many tissues they serve as a sort of internal repair system, dividing essentially without limit to replenish other cells as long as the person or animal is still alive
Market cap: $2.09 billion; current share price: $24.25 Market cap: $226.15 Million; current share price: $1.83 Market cap: $161.84 million; current share price: $1.47 Market cap: $267.60 million; current share price: $19.10 Market cap: $392.71 million; current share price: $11.25 Market cap: $64.63 million; current share price: $3.43 Market cap: $54.74 million; current share price: $5.78 Market cap: $11.05 million; current share price: $0.31 Market cap: $29.88 million; current share price: $2.75 Market cap: $28.40 million; current share price: $1.30 https://investingnews.com/daily/life-science-investing/genetics-investing/top-stem-cell-nasdaq/ https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149422974
..Bioheart, Inc. (otcqb:BHRT), a biotech company focused on the discovery, development and commercialization of autologous cell therapies, has announced that it has initiated a new clinical site in collaboration with Global Stem Cell Group in Cozumel, Mexico. The two companies have successfully treated their first congestive heart failure patient at the new clinical site last week using Bioheart's AdipoCell (adipose derived stem cells).
Global Stem Cells Group to Host Stem Cells and Regenerative ... ISSCA Physicians looking for new alternatives to improve the quality of life of their patients through emerging regenerative medicine protocols..
J. Victor Garcia Gimenez, M.D. is president of Therapeutic Confrontations (CONFTERA), is a specialist in orthopedic surgery and practices cosmetic medicine and surgery, anti-aging medicine, and aesthetic therapies in Barcelona, Spain. http://stemcellcenter.net/centers/spain/barcelona/barcelona-spain/\
ISSCA Reaches Agreement with Belgium’s Churchill Aesthetic Center Belgium’s Churchill Aesthetic Center ....The cutting-edge facility will be equipped by Adimarket, LLC, a subsidiary of the Global Stem Cells Group. Adimarket will outfit the center with equipment and supplies designed to not only teach doctors about the latest protocols in regenerative medicine but also to treat patients suffering from degenerative diseases and sports injuries. Physicians training at the facility will have access to the proven expertise of ISSCA’s global network and training protocols. http://www.stemcellsgroup.com/issca-reaches-agreement-with-belgiums-churchill-aesthetic-center/
Daeyong Kim, Ph.D. is an internationally recognized health educator, and CEO of N-Biotek, Inc, a preeminent manufacturer of biomedical and laboratory equipment. N-Biotek is a leader of stem cell technologies, providing solutions for providers worldwide.
..Dr. Zhang is an accomplished scientist, microbiologist and virologist who has worked extensively in the U.S. for the CDC, the National Institutes of Health (NIH) and the US Food and Drug Administration in various research positions, including senior associate at the National Research Center. A Chinese-American, Dr. Zhang received the Award for Scientific Achievement from the FDA
..Al Sears, M.D. often referred to as "America’s #1 anti-aging doctor," is the director of the world renowned Sears Institute for Anti-aging Medicine. Dr. Sears has published 35 books and reports on health and wellness, and has millions of loyal readers in 163 countries. Dr. Sears has been featured on ABC News, CNN and ESPN. He was one of the first specialists to be board-certified by the American Academy of Anti-Aging Medicine (A4M).
Dr. Feinerman offers stem cell treatments for a variety of disorders and diseases. He earned his medical degree from New York Medical College in 1954. Dr. Feinerman is affiliated with Long Island College Hospital in New York and Mayo Clinic in Rochester, Minnesota.
Dr. Feinerman is a member of the Society of Apheresis, Society of Bone Marrow Blood Transplantation, and the International Society for Cellular Therapy, the Society for Cranial Transplantation and Brain Repair and the Society for Cardiac Translational Therapy.